Cantor Fitzgerald Comments on PVLA FY2025 Earnings

Palvella Therapeutics (NASDAQ:PVLA) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Palvella Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn ($1.60) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $38.00 target price on shares of Palvella Therapeutics in a report on Friday, January 10th.

Palvella Therapeutics Stock Down 0.4 %

NASDAQ:PVLA opened at $13.15 on Thursday. Palvella Therapeutics has a fifty-two week low of $6.20 and a fifty-two week high of $22.32.

Insider Activity

In other Palvella Therapeutics news, Director George M. Jenkins purchased 4,000 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were bought at an average cost of $12.93 per share, for a total transaction of $51,720.00. Following the completion of the purchase, the director now directly owns 180,671 shares of the company’s stock, valued at approximately $2,336,076.03. This trade represents a 2.26 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 6.39% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.